Emily Hayes

Emily Hayes
Emily handles patent work in the life sciences field with a focus on the biotechnology and pharmaceutical sectors. Her expertise extends to: protein, nucleic acid and antibody-based therapeutics and diagnostics, genomics and post-genomics research, gene manipulation, microbiology, vaccines, diagnostic and prognostic markers. Her practice focuses on drafting and prosecuting patent applications in these and related fields, as well as handling oppositions and appeals at the EPO. She also has a special interest in US patent law, having spent time on a secondment to a US firm in 2010.

Recent Posts

Meet The Team: Emily Hayes, Partner, European Patent Attorney

Emily Hayes

Emily Hayes
28 Oct 2019

“I remember being really young, maybe six or seven, and wanting to be an inventor,” recalls Emily Hayes, adding, with a laugh – “without really knowing.

New Rules of Procedure at the Boards of Appeal – what does this mean for patentees and opponents?

Emily Hayes

Emily Hayes
09 Jul 2019

Revised Rules of Procedure at the Boards of Appeal have been approved by The Administrative Council of the EPO. The Rules will come into force on 1.

A Myriad of effects

Emily Hayes

Emily Hayes
05 Jul 2019

Even though the decision in Myriad is now 6 years old and there have been several follow-on cases, the general principles still hold true. Here, Emily.

Playing for time: strategies that can help extend a drug's patent life

Emily Hayes

Emily Hayes
25 Mar 2019

In our new magazine Forward, we interview C Hunter Baker of Wolf, Greenfield & Sacks PC.  Hunter explores a typical drug development timeline and.

Commercialising genomic research in the US: tips for obtaining patent protection

Emily Hayes

Emily Hayes
30 Jan 2019

The field of genomics has seen incredible advances over the past few decades. Technological developments coupled with decreasing costs have fuelled.